Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size

Paroxysmal Nocturnal Hemoglobinuria Treatment Market size was valued at USD 3.9 billion in 2023 and is expected to grow at a CAGR of 11.2% between 2024 and 2032. Key factors driving the market's growth include the rising prevalence of PNH, which is anticipated to increase the demand for specialized diagnostic techniques. These advancements have led to earlier and more accurate diagnoses, resulting in a larger patient population requiring treatment.

For instance, according to a report published by the U.S. Census Bureau, the prevalence of PNH in the U.S. ranged from 12 to 13 cases per 1 million people, with an estimated incidence of 5.7 per 1 million person-years. Thus, the growing advancements in diagnostic techniques and increased awareness of PNH, combined with the availability of better treatment options, have increased the life expectancy of PNH patients, leading to sustained demand for long-term treatment solutions.

PNH is a rare blood disease that causes red blood cells to break apart, releasing hemoglobin. The release of hemoglobin causes many of the symptoms associated with PNH. Treatment focuses on managing these symptoms, preventing complications, and improving the quality of life for patients. Major treatment options include complement inhibitors, bone marrow transplantation, blood transfusions, iron supplements, folic acid, and various other approaches.